{
    "clinical_study": {
        "@rank": "92267", 
        "arm_group": [
            {
                "arm_group_label": "Ad-RTS-hIL-12", 
                "arm_group_type": "Experimental", 
                "description": "Experimental study drug monotherapy arm (A), Part 1 and 2 of protocol"
            }, 
            {
                "arm_group_label": "Palifosfamide-tris", 
                "arm_group_type": "Experimental", 
                "description": "Study drug monotherapy arm (B), Part 1 of protocol"
            }, 
            {
                "arm_group_label": "Ad-RTS-hIL-12 and palifosfamide-tris", 
                "arm_group_type": "Experimental", 
                "description": "Study drug combination arm (C), in Part 1 and Part 2 of protocol"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase II, randomized, safety and efficacy study in recurrent/metastatic breast cancer with\n      accessible lesions.\n\n      Primary End point is rate of Progression Free Survival (PFS) at the 16 week treatment time\n      point. Hypothesis: Adenoviral vector (Ad-RTS-hIL-12) alone and in combination with\n      chemotherapy (palifosfamide-tris) is safe and efficacious.\n\n      2 Part study:\n\n        -  Part One: Safety run-in for Ad-RTS-hIL-12 alone arm (A) and palifosfamide-tris alone\n           arm (B). This is followed by a combination therapy (Ad-RTS-hIL-12 + palifosfamide-tris)\n           safety run-in arm (C).\n\n        -  Part Two: Efficacy evaluation of study treatment arms (A) and (C)."
        }, 
        "brief_title": "Adenoviral Vector Monotherapy or Combination With Chemotherapy Study in Subjects With Recurrent/Metastatic Breast Cancer and Accessible/Visible Lesions", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent/Metastatic Breast Cancer With Accessible Lesions", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  To be enrolled in the trial, each subject must satisfy all of the following inclusion\n             criteria:\n\n               1. Males or females of all races \u2265 18 years of age, who have provided written\n                  informed consent prior to completing any study specific procedure.\n\n               2. Histologically or cytologically confirmed adenocarcinoma of the breast, either\n                  locally recurrent or metastatic disease with injectable lesions, for which no\n                  proven effective therapy exists. Locally recurrent disease must not be amenable\n                  to surgical resection or radiation with curative intent.\n\n               3. Subject has failed or progressed on at least 1 prior systemic chemotherapy\n                  regimen \u00b1 biologic/experimental therapy (if first-line therapy, failure or\n                  progression during or within the first 30 days).\n\n               4. Resolution of all chemotherapy or radiation-related toxicities to Grade 1\n                  severity or lower, except for stable sensory neuropathy \u2264 Grade 2 and alopecia.\n\n               5. A minimum of 2 lesion(s) assessed by imaging using modified RECIST v1.1, 1 NOT\n                  to be injected AND at least 1 injectable lesion(s)(may use\n                  radiographically-guided injection of lesions if available at site)\n\n               6. ECOG performance status 0, 1, 2\n\n               7. Male and female subjects must agree to use a highly reliable method of birth\n                  control (expected failure rate less than 5% per year) from the screening visit\n                  through 28 days after the last dose of study drug. Women of childbearing\n                  potential (perimenopausal women must be amenorrheic for at least 12 months to be\n                  considered of non-childbearing potential) must have a negative pregnancy test at\n                  screening.\n\n               8. Adequate bone marrow reserve as indicated by:\n\n                    1. ANC > 1500/\u03bcL (without use of growth factors within 7 days)\n\n                    2. ALC > 700/\u03bcL (without use of growth factors within 7 days)\n\n                    3. Platelet count > 100,000/mm3 (without transfusion in prior 7 days)\n\n                    4. Hemoglobin > 9.0 g/dL (without transfusion in prior 7 days)\n\n               9. Adequate renal function as evidenced  by estimated glomerular filtration rate\n                  (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation:  eGFR \u2265\n                  60 mL/min/1.73 m2\n\n              10. Adequate liver function as evidenced by the following:\n\n                    1. Bilirubin \u2264 1.5 times the upper limits of normal (ULN)\n\n                    2. Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \u2264\n                       2.5\u00d7ULN, in the case of liver metastases \u2264 5\u00d7ULN\n\n        Exclusion Criteria:\n\n          -  Subjects will be excluded from enrolling in the trial if they meet any of the\n             following exclusion criteria:\n\n               1. Subjects with HER2/neu-positive immunohistochemistry 3+ or fluorescence in situ\n                  hybridization-amplified breast tumors who are eligible for, but who have not\n                  received HER2-targeted therapy (eg, trastuzumab)\n\n               2. Concomitant anti-cancer therapies (eg, endocrine therapy for breast cancer)\n\n               3. Prior therapies discontinuation periods:\n\n                    1. Radiation within 3 weeks of enrollment\n\n                    2. Chemotherapy within 4 weeks of enrollment\n\n                    3. Nitrosoureas within 6 weeks of enrollment\n\n                    4. Biologic therapy and/or immunomodulatory therapy (eg, G-CSF/GM-CSF,\n                       interferons or interleukins, growth hormone, IVIG, retinoic acid) within 6\n                       weeks of enrollment\n\n                    5. Prior therapy with immune checkpoint inhibitors (eg, anti-CTLA4 antibodies,\n                       anti-PD1 antibodies) within 12 weeks of enrollment\n\n                    6. No washout period is required for endocrine therapy\n\n               4. Radiation therapy encompassing >25% of bone marrow\n\n               5. History of bone marrow or stem cell transplantation\n\n               6. Any congenital or acquired condition leading to an inability to generate an\n                  immune response, including concomitant immunosuppressive therapy\n\n               7. Immunosuppressive therapy:\n\n                    1. Systemic immunosuppressive drugs including corticosteroids (prednisone\n                       equivalent >10 mg/day http://www.medcalc.com/steroid.html) within 8 weeks\n\n                    2. Immune suppression/requiring immunosuppressive drugs including subjects\n                       with organ allografts requiring any immunosuppression\n\n                    3. Active autoimmune disease requiring the equivalent of  >10 mg/day of\n                       prednisone\n\n               8. Major surgery within 4 weeks of study treatment, or major surgery planned for\n                  duration of study participation\n\n               9. History of prior malignancy, unless the prior malignancy was diagnosed and\n                  definitively treated \u22655 years previously with no subsequent evidence of\n                  recurrence NOTE: This does not apply to previous breast cancer, carcinoma in\n                  situ of the cervix, inactive melanoma or non-melanoma skin cancer, or Grade 1\n                  papillary bladder cancer\n\n              10. Subjects with brain or subdural metastases are not eligible, unless local\n                  therapy completed and corticosteroids discontinued for this indication for \u22654\n                  weeks before starting study treatment. Any signs (eg, radiologic) and/or\n                  symptoms of brain metastases must be stable for \u22654 weeks before starting study\n                  treatment; radiographic stability should be determined by comparing a\n                  contrast-enhanced computed tomography or magnetic resonance imaging brain scan\n                  performed during screening to a prior scan performed at least 4 weeks earlier.\n\n                  NOTE: Screening for brain lesions by CT or MRI is not required for all potential\n                  subjects; however, if there are any neurological signs or symptoms consistent\n                  with brain metastases, then a brain CT or MRI should be performed as clinically\n                  indicated.\n\n              11. Any medications that induce, inhibit or are substrates of CYP450 3A4 within 7\n                  days prior to the first dose of study drug\n\n              12. Subjects with meningeal carcinomatosis\n\n              13. Known significant hypersensitivity to study drugs or excipients\n\n              14. History of malabsorption syndrome or other condition that would interfere with\n                  enteral absorption\n\n              15. International Normalized Ratio (INR) and activated partial thromboplastin time\n                  [PTT] <1.5 x ULN, if not therapeutically anticoagulated. Subjects who are being\n                  therapeutically anticoagulated with an agent such as Coumadin (warfarin sodium)\n                  or subcutaneous heparin may be included provided there is no prior evidence of\n                  underlying abnormality in coagulation parameters, screening test results are in\n                  appropriate therapeutic range, and anticoagulation regimen is stable and closely\n                  monitored\n\n              16. New York Heart Association (NYHA) Class II or greater congestive heart failure\n                  OR active ventricular arrhythmia requiring medication\n\n              17. Any other unstable or clinically significant concurrent medical condition (eg,\n                  infection requiring systemic anti-infective agents) that would, in the opinion\n                  of the investigator, jeopardize the safety of a subject and/or their compliance\n                  with the protocol\n\n              18. Localized infection at site of injectable lesion(s)requiring antiinfective\n                  therapy within 2 weeks of the first dose of study drug. NOTE: Appropriate\n                  confirmatory testing (eg, punch biopsy with bacterial counts)must be performed\n                  to rule out the presence of infection if ambiguous, or clinical signs of\n                  infection are evident"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703754", 
            "org_study_id": "ATI001-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ad-RTS-hIL-12", 
                    "Ad-RTS-hIL-12 and palifosfamide-tris"
                ], 
                "description": "Oral activator ligand with adenoviral vector injection of cancer lesions", 
                "intervention_name": "Ad-RTS-hIL-12", 
                "intervention_type": "Genetic"
            }, 
            {
                "arm_group_label": [
                    "Palifosfamide-tris", 
                    "Ad-RTS-hIL-12 and palifosfamide-tris"
                ], 
                "description": "Small molecule chemotherapy, IV administration", 
                "intervention_name": "Palifosfamide-tris", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ifosfamide", 
                "Isophosphamide mustard"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Genetically Modified Organism", 
            "Metastatic Breast Cancer", 
            "Recurrent Breast Cancer", 
            "Breast Cancer", 
            "Palifosfamide", 
            "INXN1001", 
            "INXN2001", 
            "Adenoviral vector"
        ], 
        "lastchanged_date": "November 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32207"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Billings", 
                        "country": "United States", 
                        "state": "Montana", 
                        "zip": "59101"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middletown", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45042"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Germantown", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38138"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75201"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99218"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II Randomized, Open Label Study of Ad-RTS-hIL-12 Monotherapy or Combination With Palifosfamide-Tris in Subjects With Recurrent/Metastatic Breast Cancer and Accessible Lesions", 
        "overall_contact": {
            "email": "ssaleem@ziopharm.com", 
            "last_name": "Sadia Saleem", 
            "phone": "617-778-0863"
        }, 
        "overall_contact_backup": {
            "email": "gweber@ziopharm.com", 
            "last_name": "Gina Weber", 
            "phone": "617-259-2262"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability of study drug therapy based on type and rate of adverse events occurring in the treatment population", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 24 weeks-Beginning from the time a patient signs the informed consent to the Follow up Tumor Assessment visit"
            }, 
            {
                "measure": "16-week PFS rate, calculated as the number of subjects who had not progressed or died prior to 16 weeks from the date of their first dose, divided by the number of subjects in the study arm.", 
                "safety_issue": "No", 
                "time_frame": "16 weeks, starting at the date the first dose of study drug is administered"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703754"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of subjects achieving a confirmed PR or CR according to modified RECIST v1.1", 
                "measure": "Objective response rate (ORR) by modified RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "Approximately 24 weeks- From first study drug dose to Follow-Up Tumor Assessment Visit"
            }, 
            {
                "measure": "Clinical Benefit rate: proportion of subjects with CR, PR, or SD by modified RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "Approximately 24 weeks"
            }, 
            {
                "measure": "Estimate PFS by modified RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "Approximately 24 weeks, beginning at the first study drug administratrion and ending at the Follow up Tumor Assessment visit"
            }, 
            {
                "measure": "Evaluate Pharmacodynamic tumor markers in tumor tissue samples that may correlate with objective tumor response and/or clinical outcome", 
                "safety_issue": "No", 
                "time_frame": "Approximately 24 weeks, starting with first study drug administrationa and ending at the Follow up Tumor Assessment visit"
            }
        ], 
        "source": "Ziopharm", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ziopharm", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}